A method of diagnosing the risk that a subject has or has an increased risk of developing overactive bladder syndrome is described. The method includes detecting the levels of choline and/or acetylcholine in a biological sample from the subject, comparing the detected levels to reference values, and characterizing the subject as having an increased risk of having or developing overactive bladder syndrome if the choline and/or acetylcholine values are higher than the reference values. Kits for determining choline and/or acetylcholine levels in a subject, and methods of treating a subject for overactive bladder syndrome are also described.

The invention provides a method of diagnosing overactive bladder disorder (OAB), the method comprising: measuring the concentrations of one or more of adenosine triphosphate (ATP), acetylcholine (ACh), nitric oxide (NO) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001; ACh/Cr to 0.1; NO to 20000; IL-5/Cr to 100; wherein the likelihood of having OAB (p.sub.OAB)=1/1+e.sup.−x, where X=one or more of the following: (a) (−2.688±1.050)+5.472±2.098×subject's age+1.356±0.559×Gender (Female=1, Male=0)+(−7.998±40.273)×[IL-5/Cr]; (b) (−2.141±0.966)+4.506±1.902×subject's age+1.034±0.519×Gender (Female=1, Male=0)+(−5294.063±9075.456)×[ACh/Cr]; (c) (−2.825±1.072)+5.964±2.167×subject's age+1.312±0.562×Gender (Female=1, Male=0)+17.790±58.762×[IL-5/Cr]+(−9180.821±12700.057)×[ACh/Cr]; (d) (−2.993±1.197)+5.580±2.309×subject's age+1.724±0.719×Gender (Female=1, Male=0)+63.571±73.444×[IL-5/Cr]+(−0908.523±13606.752)×[ACh/Cr]+(−566.991±636.589)×[ATP/Cr]; (e) (−3.090±1.200)+5.393±2.256×subject's age+1.797±0.717×Gender (Female=1, Male=0)+34.767±56.331×[IL-5/Cr]+(−562.743±629.316)×[ATP/Cr]; or (f) (−2.650±1.067)+5.516±2.120×subject's age+1.389±0.583×Gender (Female=1, Male=0)+(−4.060±45.238)×[IL-5/Cr]+(−1.456±6.833)×[NO/Cr]; and wherein a pOAB above a threshold indicates that the subject has a high likelihood of having or developing OAB and a pOAB below a threshold indicates that the subject does not have OAB.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The present invention relates to a method of diagnosing over active bladder disorder (OAB), the method comprising: measuring the concentrations of adenosine triphosphate (ATP), acetylcholine (ACh), nitrite, monocyte chemoattractant protein 1 (MCP-1) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001 mole/mgxdl.sup.1; ACh/Cr to 0.1 mole/mgxdl.sup.1; Nitrite to 200 nM/mgxdl.sup.1; MCP-1/Cr to 100 pgxml.sup.1/mgxdl.sup.1; IL-5/Cr 100 pgxml-mgxdl.sup.1; applying the normalised and range standardised concentrations to the following formula: Logit (p)=1.7381.4044.9852.914subject's age+3315.9595435.254[ATP]/[Cr]+(25204.19420268.337)[ACh]/[Cr]+26.79932.967[nitrite]/[Cr]+6.75525.132 [MCP-1]/[Cr]+(61.838148.740) [IL-5]/[Cr] and calculating Logit; wherein a Logit value above a predetermined threshold indicates that the subject has OAB. Methods for monitoring the progression of OAB using the method, kits for use in the method and computer systems and programs configured to execute the method are also provided.

The present invention relates to a method of diagnosing over active bladder disorder (OAB), the method comprising: measuring the concentrations of adenosine triphosphate (ATP), acetylcholine (ACh), nitrite, monocyte chemoattractant protein 1 (MCP-1) and interleukin 5 (IL-5) in a sample obtained from a subject; normalising the concentrations to the concentration of creatinine (Cr) in the sample; range standardising the normalised concentrations and subject's age to the following values: Age to 120 years old; ATP/Cr to 0.000001 mole/mgdl.sup.1; ACh/Cr to 0.1 mole/mgdl.sup.1; Nitrite to 200 nM/mgdl.sup.1; MCP-1/Cr to 100 pgml.sup.1/mgdl.sup.1; IL-5/Cr 100 pgml-mgdl.sup.1; applying the normalised and range standardised concentrations to the following formula: Logit (p)=1.7381.4044.9852.914subject's age+3315.9595435.254[ATP]/[Cr]+(25204.19420268.337)[ACh]/[Cr]+26.79932.967[nitrite]/[Cr]+6.75525.132 [MCP-1]/[Cr]+(61.838148.740) [IL-5]/[Cr] and calculating Logit; wherein a Logit value above a predetermined threshold indicates that the subject has OAB. Methods for monitoring the progression of OAB using the method, kits for use in the method and computer systems and programs configured to execute the method are also provided.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.